MDXG Earnings Prediction
The chart below shows how MDXG performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MDXG sees a -0.80% change in stock price 10 days leading up to the earnings, and a +9.30% change 10 days following the report. On the earnings day itself, the stock moves by -0.15%. This data can give you a slight idea of what to expect for the next quarter's release.
MDXG Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
84.06M
2.87%
-3.61%
Gross Margin
81.54%
-0.16%
-1.46%
Operating Margin
14.41%
7.22%
-8.62%
Net Margin
9.37%
-10.25%
-53.64%
EPS
0.05
-16.67%
-58.33%
No Data Available
MDXG Earnings Analysis
MiMedx Group, Inc Corporation (MDXG.O) Earnings Conference Call
Positive
Top Line Growth Achieved: For the third quarter, we once again achieved year-over-year top line growth and maintained an excellent operating margin despite the challenges in the private office and associated care settings due to the massive abuse of the Medicare reimbursement system being perpetrated in those sectors.
Medicare Revenue Impact: We generated approximately 25% of our revenue from Medicare fee-for-service patients in the areas being impacted by this fraudulent activity.
Net Sales Increase: Net sales grew year-over-year by $2 million or 3% to $84 million, in line with the expectations we highlighted on our last call and marking another solid growth quarter.
High Gross Profit Margin: Gross profit margin was 82%.
Adjusted EBITDA Increase: Adjusted EBITDA was $18 million or 22% of net sales in the quarter, representing an increase of $600,000 over the prior year period.
Negative
Net Sales Growth Slowdown: Net sales for Q3 2024 were $84 million, representing only 3% growth compared to the prior year period, indicating a slowdown in growth.
Surgical Sales Decline: Surgical sales of $29 million were down 5% compared to the prior year period, reflecting a decline in this segment.
Financial Performance Weakness: Despite a 3% increase in gross profit margin, the overall financial performance showed signs of weakness with adjusted EBITDA remaining flat at $18 million or 22% of net sales.
Hospital Channel Decline: The hospital channel experienced a decline of 3% compared to the prior year quarter, largely due to disruptions caused by higher-than-expected employee churn.
Rising Operating Expenses: Operating expenses increased to $54 million in Q3 compared to $53 million in the prior year period, indicating rising costs that could impact profitability.
MDXG FAQs
How does MDXG typically perform around its earnings report dates?
Is MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MDXG Earning Call Sentiment
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
MDXG.O
-1.55%Positive
The earnings call summary presents a mixed outlook. Financial performance shows modest growth, with stable gross margins and increased cash flow. However, challenges persist, including reimbursement issues, operational disruptions, and economic uncertainties. The Q&A session reveals management's uncertainty regarding future reimbursement and manufacturing initiatives. Despite some optimism, such as strong customer portal adoption and international sales growth, the overall sentiment is balanced by these concerns. Without a clear market cap, the stock price is likely to remain neutral, fluctuating between -2% to 2% over the next two weeks.